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BACKGROUND: There is a need to develop blood-based bioassays for breast cancer (BC) screening. In this study, differential gene
expression between BC samples and benign tumours was used to identify candidate biomarkers for blood-based screening.
METHODS: We identified two proteins (Fibronectin 1 and CXCL9) from a gene expression data set that included 120 BC samples and
45 benign lesions. These proteins fulfil the following criteria: differential gene expression between cancer and benign lesion, protein
released in the extracellular medium and stable in the serum, commercially available ELISA kit, ELISA accuracy in a feasibility study.
Protein concentrations were determined by ELISA. Blood samples were from normal volunteers (n¼119) and early BC patients
(n¼133).
RESULTS: Seventy-three per cent of patients had cT1-T2 tumour. Patients had higher CXCL9 and Fibronectin 1 concentrations than
volunteers. CXCL9 mean concentration was 851 and 635pgml
 1 for patients and volunteers respectively (P¼0.013). CXCL9
concentration was significantly higher in patients with estrogen receptor (ER)-negative compared with volunteers (P¼0.003), data
consistent with gene expression profile. Fibronectin 1 mean concentration was 190mgml
 1 for patients and 125mgml
 1 for
volunteers (Po0.001). Areas under the curve for BC diagnosis were 0.78 and 0.62 for Fibronectin 1 and CXCL9 respectively.
A combined score including Fibronectin 1 and CXCL9 dosages presented 53% of sensitivity and 98% of specificity. Similar
performances were observed for ER-negative tumours.
CONCLUSIONS: This study suggests that Fibronectin 1/CXCL9 dosage in serum could screen a significant rate of BC, including
ER-negative, and that differential gene expression analysis is a good approach to select candidate biomarkers to set up blood assays
cancer screening.
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Breast cancer (BC) is the most frequent cancer in women. World
estimation is 850000 new cases per year with 340000 deaths per
year. In 2005, France had reported 49814 new cases. Although
several advances (mammogram screening and post-operative
treatments) have allowed improvements in 5-year survival in this
disease, more than 11000 women died of BC in France (La
situation du cancer en France). Breast cancer incidence in the
European population in 2006 was 29%, with a mortality rate of
18% (Karim-Kos et al, 2008). Early diagnosis could decrease BC
mortality by means of cancer downstaging. As an illustration,
randomised studies have shown that mammogram screening
decreases the BC death rates by 21% (Nystrom et al, 2002).
Although mammogram screening has allowed an undisputable
benefit, it has several limitations. First, it is associated with a
significant rate of false-positive results, leading to unnecessary
biopsies or surgeries (Fletcher and Elmore, 2003; Delaloge et al,
2005). Second, this technology mainly detects slowly proliferating
tumours that occur after the age of 50 years, but exhibits poor
performance to screen aggressive tumours, especially in young
women in whom breast density is high. Finally, although mass
screening by mammogram has been well implemented in most of
the European countries, 20% of the population are still not
compliant with it (Hakama et al, 2008). These patients usually
present poor income and are excluded from this medical advance.
Based on the observation that a mammogram offers a significant,
but suboptimal, screening for BC, new approaches have been
tested to improve BC detection. New radiological technologies
have been tested in this setting. MRI has been shown to detect
most of the cancers early, including those in younger women, but
this approach is limited by a high rate of false-positive results,
together with a high cost. Ultrasonography, combined with a
mammogram, also increases the likelihood of BC detection, but is
once again associated with high rate of false positivity.
Until now, no serum biomarker has been shown to allow an
early diagnosis of BC. As a consequence, current ASCO guidelines
do not recommend the use of serum biomarker (CA15-3, CEA) for
BC screening (Harris et al, 2007).
These data point out the need to develop new easy-to-do
tests that would improve BC detection and decrease the rate of
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sfalse-positive results associated with radiological examinations. In
this study, we aimed at generating a blood-based assay that could
screen BC. To achieve this goal, we first identified genes
overexpressed in BC compared with benign lesions. We then
determined which of these genes encoded for proteins released in
the extracellular medium. Finally, we performed dosage of these
proteins in the blood of overall 252 BC or normal volunteers to
determine whether these proteins were more concentrated in
patients with BC.
PATIENTS AND METHODS
Identification of candidate proteins for breast cancer
screening
To identify which genes were overexpressed in BC, we used a
public data set of exon arrays (Andre et al, 2009). This data set
includes 120 BC and 45 benign lesions. Samples were obtained by
fine needle aspiration of breast lesions. Gene expression levels
were determined as previously reported. The strategy used to select
candidate biomarkers for blood-based screening is reported in
Figure 1A. Genes overexpressed in BC (42-fold increase and
FDRo0.05) that encode for a protein released in the extracellular
medium were selected for further analyses. To determine which
genes encoded for a protein released in extracellular medium,
we looked at the protein location in UniProt Knowledgebase
(UniProtKB) section Swiss-Prot, to obtain functional informa-
tion on proteins (http://www.uniprot.org/). Nevertheless, other
methods of protein identification could be used. For example, we
could use a difference between including Signal P and TMHMM
databases. Signal P ((http://www.cbs.dtu.dk/services/SignalP/))
and TMHMM ((http://www.cbs.dtu.dk/services/TMHMM/) recog-
nise signal peptides at the N-terminal and transmembrane regions
respectively. Proteins predicted by Signal P but not TMHMM could
be secreted in the serum, and therefore represent a potential target
for ELISA.
Of the proteins released in extracellular medium, we only kept
for further analyses those for which an ELISA could be set up using
commercially available antibodies. This approach allowed us to
identify five candidate proteins (Fibronectin 1, CXCL9, CEACAM5,
CHTRC1 and Complement factor B). Of these five, Complement
Factor B (CFB) will no longer be considered, as the protein is
unstable in serum.
Patient selection
Concentrations of candidate biomarkers were assessed in serum
samples from 133 women with breast adenocarcinoma and 119
healthy women. Breast cancer patients were retrospectively
selected to have presented a primary BC without metastases at
diagnosis between 1999 and 2006. Blood samples were obtained at
the time of diagnosis. Normal volunteers were healthy blood
donors. They presented neither fever, nor cancer history, nor
chronic infectious disease (HCV, HBV, HIV) history. As normal
volunteers were aged between 18 and 62 years, we focused the
analysis of samples from cancer patients in women aged between
18 and 60 years.
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Figure 1 (A) Selection of the three candidate proteins for analyses of serum samples. (B) Gene expression levels for the five candidate genes in cancer
and benign lesions.
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sSample processing
Archived serum specimens were obtained from the Biological
Resource Center of Gustave Roussy Institute. All samples have
consent in accordance with approval granted by the ethics
committee of the medical centre. Control sera were obtained in
2008 with a signed informed consent from normal volunteers of
the French Blood Institution. All samples were centrifuged and
aliquoted after collection and stored at  801C until the assays
were performed. No repeat freezing or thawing was permitted.
ELISA
Three proteins were measured with commercially available enzyme
immunoassay kits. Human MIG ELISA set BD OptEIA (Ref. 550998;
BD Biosciences–Pharmingen, Franklin Lakes, NJ, USA) was used to
determine CXCL9 concentration. Fibronectin 1 was measured with
Human Fibronectin ELISA BMS2028 (Bender MedSystems, San
Diego, CA, USA). Carcinoembryonic antigen-related cell adhesion
molecule 5 (CEACAM5) concentrations were assessed using Carcino-
embryonic Antigen Enzyme Immunoassay Test Kit (catalog no.
07BC-1011; MP Biomedicals, Solon, OH, USA). All the measurements
were performed following the manufacturer’s instructions.
As no ELISA was commercially available for CHTRC1, the
ELISAs were set up in house (not shown). Nevertheless, positive
controls were not detected for CHTRC1. This latter biomarker was
not further explored in this study.
Absorbance was read at 450nm using a spectrophotometer (ELx808;
Fisher Bioblock Scientific, Pittsburgh, PA, USA). Sera concentration of
each protein was interpolated from a standard curve, which was
generated using the respective purified or recombinant protein.
ELISAs were first applied to a set of 23 blood samples that
included 14 BC patients. If a protein was detected, the ELISA was
then performed in the study population (n¼252).
Statistical analyses
Statistical significance was determined with Student’s t-test (two
tailed) comparison between two groups of data sets. A P-value
o0.05 was considered significant. The area under an ROC curve
(AUC) is a measure of the overall discriminatory power of the
marker (with AUC 1.0 corresponding to perfect prediction and
AUC 0.50 corresponding to no discrimination) and was calculated
with SPSS software version 15.0 (Chicago, IL, USA).
RESULTS
Selection of candidate biomarkers for analyses of serum
samples
The process for selection of candidate proteins is reported in
Figure 1A. We first identified candidate genes in a data set of exon
expression arrays that included 120 BCs and 45 benign lesions
(Andre et al, 2009). Gene expression levels were defined as previously
described. Of the 72 genes that presented more than a twofold
increase in cancer compared with benign lesions, 5 were selected to
encode for a protein detectable by ELISA and released in the
extracellular medium (Swiss-Prot). These five genes include Fibro-
nectin 1, MIG1 (CXCL9), CFB, Collagen triple helix repeat containing
1 (CTHRC1) and CEACAM5. Figure 1B reports the gene expression
levels for these five candidate genes in malignant and benign breast
lesions. We then assessed whether these five candidate genes were
differentially expressed according to estrogen receptor (ER) expres-
sion. Fibronectin 1 and CFB were overexpressed in ER-positive
compared with ER-negative disease (P¼0.02 and 0.004 respectively,
t-test). Conversely, MIG1 was overexpressed in ER-negative com-
pared with ER-positive disease (P¼0.05, t-test; data not shown).
We then assessed the feasibility of ELISA for the five candidate
proteins. CEACAM5 was not detectable in the 23 samples tested.
In addition, it was not possible to obtain any signal with recombi-
nant protein (positive control) for CTHRC1, although ELISA
provided a signal in some of the 23 samples. For CFB, Fibronectin
1 and CXCL9, standard curve provided a consistent signal and
protein was detectable in at least 1 of the 23 samples. As CFB is
unstable, only CXCL9 and Fibronectin 1 will therefore be analysed.
Patient characteristics for the serum biomarker study
The serum biomarker study was performed on 252 samples from
either normal volunteers (n¼119) or women with non-metastatic
breast adenocarcinoma (n¼133). Samples were obtained between
diagnosis and first treatment for all the patients. Patient
characteristics are reported in Table 1. Briefly, 73% of the patients
presented a cT1-T2 tumour; 34% and 22% of the tumours were
ER-negative and Her2þþþ respectively. CA15-3 concentration
was assessed in 133 patients. Only 14% of these patients presented
an elevation of CA15-3 (X30IUml
 1), suggesting that conventional
serum markers could not screen patients in this study population.
Fibronectin 1 serum concentration in cancer patients vs
normal volunteers
Fibronectin 1 concentration was not associated with any
clinicopathological characteristics in cancer patients, except age
Table 1 Patient characteristics
Characteristics n¼133 (100%)
Median age at diagnosis (range) 47 (32–60)
Clinical tumour size
T1 25 (19)
T2 72 (54)
T3-T4 34 (25.5)
Unknown 2 (1.5)
Histology
Ductal in situ 2 (1.5)
Ductal invasive 101 (76)
Lobular invasive 12 (9)
Other 18 (13.5)
Nodes
0 20 (15)
1–3 18 (13.5)
43 15 (11.5)
Not assessable (preoperative chemotherapy) 80 (60)
ER
Positive 85 (64)
Negative 46 (34.5)
Unknown 2 (1.5)
PR
Positive 70 (52.5)
Negative 61 (46)
Unknown 2 (1.5)
Her-2 neu
Positive 30 (23)
Negative 76 (57)
Unknown 27 (20)
Histological grade
I 10 (7.5)
II 64 (48)
III 50 (37.5)
Unknown 9 (7)
Abbreviations: ER¼estrogen receptor; PR¼progesterone receptor.
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s(Po0.001; Table 2). As reported in Figure 2, the serum concen-
tration of Fibronectin 1 was higher in cancer patients (mean: 190,
min: 11, max: 326mgml
 1) compared with normal volunteers
(mean: 125, min: 58, max: 212mgml
 1)( Po0.001). Fibronectin 1
concentrations according to cancer status and ER expression are
reported in Figure 3.
The metric performances of Fibronectin 1 for BC diagnosis are
reported in Table 3. Area under the curve was 0.77 when a cutoff of
150 was chosen, with a 75% sensitivity and 80% specificity. When
the analysis focused on ER-negative BC, sensitivity was 72% and
specificity was 79% (overall accuracy¼77%).
When a cutoff of 200mgml
 1 was chosen, the sensitivity and
specificity were 43 and 98%, respectively. Using this cutoff, the
positive predictive value was 97%.
CXCL9 serum concentration in cancer patients vs normal
volunteers
The CXCL9 serum concentrations according to clinical character-
istics are reported in Table 2. The average CXCL9 serum
concentrations were 999 and 773 in patients with ER-negative
and -positive disease (P¼0.07, t-test), data consistent with gene
expression data. As reported in Figure 2, the serum concentration
of CXCL9 was higher in cancer patients (mean: 851, min: 121, max:
3941pgml
 1) compared with normal volunteers (mean: 635, min:
12, max: 4327pgml
 1)( P¼0.013). When the analyses focused on
ER-negative disease, the difference between BC samples (mean
concentration: 999) and normal volunteers (mean concentration:
635) was statistically significant (P¼0.003, t-test). At the opposite
end, CXCL9 concentrations were not different between ER-positive
BC (mean concentration: 773) and normal volunteers (mean
concentration: 635) (P¼0.14). CXCL9 concentrations according to
cancer status and ER expression are reported in Figure 3.
The metric performances of CXCL9 for BC diagnosis are reported in
Table 3. Area under the curve was 0.624 when a cutoff of 750pgml
 1
was chosen, with a sensitivity of 45% and specificity of 79%. When the
analyses focused on ER-negative disease, using the same cutoff at
750pgml
 1, sensitivity and specificity were 57 and 80% respectively.
Overall accuracy was 73% for the detection of ER-negative BC.
When a cutoff of 1000pgml
 1 was chosen, sensitivity was 27%
and specificity was 90%. Using this cutoff, the positive predictive
value was 76%.
Combined detection of FN1 and CXCL9 for breast cancer
detection
As stated in the beginning, the objective of serum marker for BC
screening would be to increase the performance of a mammogram.
Table 2 CXCL9 and Fibronectin 1 median serum concentrations
according to clinical characteristics
Characteristics
(n¼133)
CXCL9
(pgml
 1) P
Fibronectin 1
(lgml
 1) P
Age
o35 683 0.27 128 o0.001
435 788 177
Clinical tumour size
T1 874 206
T2 791 0.69 186 0.35
T3 953 184
T4 1003 199
Histology
Ductal in situ 766 222
Ductal invasive 845 0.05 191 0.27
Lobular invasive 593 187
Nodes
0 882 186
1–3 762 0.35 190 0.78
4–9 1044 196
49 711 202
ER
Positive 773 0.07 190 0.89
Negative 999 189
PR
Positive 761 0.09 192 0.54
Negative 957 187
Her-2 neu
Positive 888 0.29 186 0.71
Negative 741 182
Histological grade
I 728 0.21 182 0.62
II 774 187
III 998 196
Abbreviations: ER¼estrogen receptor; PR¼progesterone receptor.
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Figure 2 Serum concentration of CXCL9 and Fibronectin 1 in cancer vs normal volunteers.
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sOverall, the screening test is expected to be a combination between a
serum marker and a mammogram. The goal would be to detect an
optimal rate of BC (including ER-negative BC) while keeping a
maximal positive predictive value and specificity to avoid unneces-
sary exams for false-positive results. We considered cases with
Fibronectin 1o150pgml
 1 as negative and those with Fibronectin
14200pgml
 1 as positive. For intermediate concentrations
(150oFibronectin 14200pgml
 1), patients with CXCL9 concentra-
tions 41000pgml
 1 were considered as positive, and those with
CXCL9o1000pgml
 1 were considered as negative. Using this
algorithm, we found that 73 and 177 cases were positive and
negative respectively. The sensitivity to detect cancer was 53% and
specificity was 97%. The positive predictive value was 96%. This
score allowed detection in 25 out of 46 ER-negative BCs (54%).
DISCUSSION
In this study, we have reported that CXCL9 and Fibronectin 1
serum concentrations are higher in BC patients compared with
normal volunteers. CXCL9 is an interferon-induced chemo-
kine, involved in T-cell attraction (Liao et al, 1995; Gasperini
et al, 1999). Several studies have shown that CXCL9 is released
by cancer cells, including melanoma (Kunz et al, 1999) or renal
cancer cell (Bukowski et al, 1999). Fibronectin 1 is a glyco-
protein involved in cell–matrix and cell–cell adhesion, cell
migration and oncogene transformation (Gould et al, 1990), as
well as in tumour invasion and metastasis (Yamada et al, 1985;
Schwartzbauer, 1988; Humphries and Yasuda, 1988; Couchman
et al, 1990).
The two proteins, Fibronectin 1 and CXCL9, were identified by
the analysis of differentially expressed genes between malignant
and benign lesions of the breast. This strategy could be extended
for other frequent tumour types, including lung cancer (Humphries
and Yasuda, 1988), for which new screening tools are needed.
Optimal BC screening is expected to decrease tumour size and
lymph node involvement at diagnosis. Unfortunately, BC screening
by mammogram misses a significant rate of BC (interval cancer)
and is associated with a high rate of false-positive results, requiring
unnecessary biopsies. This latter point is particularly true for new
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Figure 3 CXCL9 and Fibronectin 1 serum concentrations according to cancer status and ER expression.
Table 3 Metric performance of Fibronectin 1 and CXCL9 dosages for BC diagnosis
Sensitivity
(%)
Specificity
(%)
Positive predictive
value (%)
Negative predictive
value (%)
Accuracy
(%) AUC 95% CI P
MIG 750mgml
 1 45 79 71 56 73 0.624 0.55–0.69 0.001
MIG 1000mgml
 1 28 90 76 52 57 0.588 0.51–0.65 0.016
FN1 150pgml
 1 75 80 81 74 77 0.778 0.71–0.83 o0.001
FN1 200pgml
 1 42 98 97 60 41 0.706 0.64–0.70 o0.001
Abbreviation: AUC¼area under the curve.
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stechnologies including MRI. With the current cutoff, the
present serum marker exhibits average sensitivity but high
specificity and positive predictive value. When combined with a
mammogram, this test is expected to improve the detection of BC
modestly. The resulting performance will be an increased
sensitivity for the screening test. If developed in combination with
a mammogram, it is important for the test to present a high
specificity to avoid additional false-positive results to the ones of
mammogram. Also, with a high specificity biopsy could be avoided
and surgery be performed in patients with ACR4/5 lesion who
present a positive serum screening. Finally, adding a serum test
with high negative predictive value to mammogram could also
improve patient care by avoiding unnecessary biopsy in patients
with ACR4 mammograms. This test presents only modest negative
predictive values and will not avoid biopsies in these latter patients.
Integration of the Fibronectin 1/CXCL9 score in a screening and
post-screening programme could allow both to increase the rate of
detected cases and to decrease the rate of unnecessary biopsies.
The Fibronectin 1/CXCL9 score looks particularly interesting to
detect ER-negative BCs (54% detection). Mass screening is
associated with poor detection of these aggressive BCs. In a recent
study (Yang et al, 2008), it was suggested that for triple-negative
BC, mammogram may not be the ideal imaging technique. This is
related to both the radiological (lack of microcalcification,
occurrence in high-density BC) and the biological (high prolifera-
tion rates) features of such cancers. The present data suggest that
Fibronectin 1/CXCL9 score could allow to screen a significant rate
of patients with ER-negative BC.
Several studies have evaluated the use of serum biomarkers for
BC care. None of these studies could identify a robust marker for
BC screening. Some studies have shown that although pre-
operative CA15-3 has a prognostic relevance (Shering et al,
1998), others do not (Ebeling et al, 2002). Some data support that
CEA is a strong independent prognostic factor for disease-free
survival and death from disease (Ebeling et al, 2002). Also, these
two markers have been studied in the monitoring of treatment
efficacy; however, both were related to be poor prognostic markers
for determining progression (Bartsch et al, 2006).
Some bioassays have been set up with the aim of screening BC
patients. Several reports (Tamkovich et al, 2005; Huang et al, 2006)
have suggested that the concentration of tumoural DNA was higher
in the serum of BC patients compared with healthy volunteers.
Proteomics is another promising technology for BC screening and
diagnosis (Davis and Hanash, 2006). Nevertheless, none of these
bioassays has shown enough performance to be transferred onto
clinical practice.
Although this study reports two candidate proteins that could
screen a significant rate of patients with BC, it presents several
limitations. First, no validation set has been included in the
analysis. A prospective clinical study is ongoing that will better
assess the metric performance of the bioassay. Second, the
population of normal volunteers included blood donors who are
selected for not presenting any symptom or acute disease. Further
validation will need to select negative controls carefully. Finally,
the sensitivity of the test needs improvements. Additional proteins
will be included in the bioassay. These proteins have been selected
to be encoded by genes overexpressed in BC, but for which no
ELISA was feasible.
In conclusion, analysis of differential gene expression between
cancer and normal tissue allows the identification of candidate
proteins for blood-based cancer screening.
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